URGN

Urogen Pharma Ltd

Add to Watchlist

Advanced Chart

18.240

+0.495(2.790%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.385

Open

17.480

VWAP

17.79

Vol

889.06K

Mkt Cap

843.86M

Low

17.210

Amount

15.81M

EV/EBITDA(TTM)

Total Shares

41.13M

790.25M

EV/OCF(TTM)

P/S(TTM)

9.24

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

45.81M

+126.19%

-0.610

-33.7%

44.31M

+80.36%

-0.314

-60.75%

33.57M

+33.19%

-0.588

+6.91%

Estimates Revision

The market is revising Upward the revenue expectations for UroGen Pharma Ltd. (URGN) for FY2025, with the revenue forecasts being adjusted by 1.22% over the past three months. During the same period, the stock price has changed by 63.73%.

Revenue Estimates for FY2025

Revise Upward

+1.22%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+28.64%

In Past 3 Month

Stock Price

Go Up

+63.73%

In Past 3 Month

8 Analyst Rating

72.70% Upside

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 31.50 USD with a low forecast of 16.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

72.70% Upside

Current: 18.240

Low

16.00

Averages

31.50

High

50.00

72.70% Upside

Current: 18.240

Low

16.00

Averages

31.50

High

50.00

H.C. Wainwright

Neutral -> Buy

upgrade

$50

2025-06-17

Reason

H.C. Wainwright

Price Target

$50

2025-06-17

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded UroGen Pharma to Buy from Neutral with a $50 price target. The company announced that the FDA had approved Zusduri, the first and only FDA-approved medication for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, the analyst tells investors in a research note. The firm says the approval "represents a highly welcome result and a positive surprise" in the wake of last month's negative FDA panel vote.

Guggenheim

NULL -> Buy

upgrade

$15 -> $30

2025-06-13

Reason

Guggenheim

Price Target

$15 -> $30

2025-06-13

upgrade

NULL -> Buy

Reason

Guggenheim raised the firm's price target on UroGen Pharma to $30 from $15 and keeps a Buy rating on the shares. The FDA announced the full approval of "Zusduri" one day ahead of the PDUFA deadline date in "a surprise decision" following the negative ODAC vote during an FDA advisory committee meeting last month, the analyst tells investors. The firm believes this outcome represents "a best-case-scenario" for UroGen given that the marketing approval indicates a broad indication of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, without the need to conduct another large randomized controlled trial and "only minor safety warnings."

Scotiabank

Outperform

upgrade

$23 -> $47

2025-06-13

Reason

Scotiabank

Price Target

$23 -> $47

2025-06-13

upgrade

Outperform

Reason

Scotiabank raised the firm's price target on UroGen Pharma to $47 from $23 and keeps an Outperform rating on the shares. The firm is increasing its FDA approval likelihood from 60% to 100% and raised its price target based on its current view of a peak ZUSDURI market opportunity of about $1B, the analyst tells investors.

Oppenheimer

Leland Gershell

Outperform

maintain

$10 -> $31

2025-06-13

Reason

Oppenheimer

Leland Gershell

Price Target

$10 -> $31

2025-06-13

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on UroGen Pharma to $31 from $10 and keeps an Outperform rating on the shares following yesterday's approval of Zusduri. The firm says key reveal on this morning's conference call was the $21,500 per-dose list price. Oppenheimer awaits clarity on the approval path for UGN-103, which is needed to extend franchise exclusivity beyond early 2031, but notes management does not expect the potential need for a randomized controlled trial in lieu of the recently-initiated single-arm study to materially alter its financial outlook. The analyst sees $1B in sales over time and would would take advantage of any near-term weakness to buy UroGen shares.

Goldman Sachs

Paul Choi

Neutral

maintain

$3 -> $16

2025-06-13

Reason

Goldman Sachs

Paul Choi

Price Target

$3 -> $16

2025-06-13

maintain

Neutral

Reason

Goldman Sachs analyst Paul Choi raised the firm's price target on UroGen Pharma to $16 from $3 and keeps a Neutral rating on the shares following yesterday's approval of Zusduri. The firm cites the stock being bid up (+22% following FDA approval of Zusduri in patients with low-grade intermediate-risk non muscle-invasive bladder cancer, which was surprising to most investor expectations given the negative ODAC advisory committee briefing document and vote that the drug's overall benefit-risk profile was not favorable, the analyst tells investors in a research note. Although the FDA is not obligated to follow the ODAC's recommendation, approvals following negative advisory committee meeting votes, particularly in oncology, are exceedingly rare, the firm adds.

Oppenheimer

Leland Gershell

Outperform

downgrade

$36 -> $10

2025-06-03

Reason

Oppenheimer

Leland Gershell

Price Target

$36 -> $10

2025-06-03

downgrade

Outperform

Reason

Oppenheimer analyst Leland Gershell lowered the firm's price target on UroGen Pharma to $10 from $36 and keeps an Outperform rating on the shares. The firm says investor interest following its prior UroGen note inspired Oppenheimer to value the stock by building out its working financial model for the company. The firm believes its updated model offers investors an accessible means of valuing UroGen as a function of the likelihoods that UGN-102 and, eventually, UGN-103, are approved. Despite lowering its price target, Oppenheimer is more optimistic on near-term UGN-102 approval than the market is indicating.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is -8.41, compared to its 5-year average forward P/E of -3.61. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.61

Current PE

-8.41

Overvalued PE

-2.28

Undervalued PE

-4.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.77

Current EV/EBITDA

-9.53

Overvalued EV/EBITDA

-1.64

Undervalued EV/EBITDA

-5.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.81

Current PS

4.75

Overvalued PS

7.51

Undervalued PS

2.11